My Library

University LibraryCatalogue

For faster,
simpler
access.
Use Lean
Library.
Get it now
Don't show me again

LEADER 00000cam a2200445 i 4500 
003    OCoLC 
005    20180804040342.4 
006    m     o  d f       
007    cr un||||||||| 
008    141104s2012    mdua    on   f000 0 eng   
019    NCBIBSocn904787038 
040    NLM|beng|erda|cNLM|dOCLCO|dVT2|dOCLCQ|dOCLCO|dOCLCA 
042    pcc 
049    MAIN 
060 00 WK 835 
100 1  Milne, Andrea,|eauthor. 
245 10 Measuring health-related quality of life for patients with
       diabetic retinopathy /|cUniversity of Alberta Evidence-
       based Practice Center ; Andrea Milne, Jeffery A. Johnson, 
       Matthew Tennant, Christopher Rudnisky, Donna M. Dryden. 
264  1 Rockville, Maryland :|bAgency for Healthcare Research and 
       Quality,|cApril 23, 2012. 
300    1 online resource (1 PDF file (various pagings)) :
       |billustrations. 
336    text|btxt|2rdacontent 
337    computer|bc|2rdamedia 
338    online resource|bcr|2rdacarrier 
490 1  Technology assessment report 
500    Title from PDF title page. 
520 3  OBJECTIVES: To identify and evaluate the psychometric 
       properties of tools used to measure health-related quality
       of life (HRQL) in patients receiving treatment for 
       diabetic retinopathy (DR), and to assess the effectiveness
       of interventions for DR to improve HRQL. DATA SOURCES: We 
       conducted a systematic and comprehensive search in six 
       electronic databases and hand searched reference lists of 
       reviews and included studies. REVIEW METHODS: Study 
       selection, quality assessment, and data extraction were 
       completed by reviewers independently and in duplicate. We 
       included articles that presented data on HRQL outcomes 
       following an intervention for DR (including diabetic 
       macular edmema (DME). Mean differences and 95 percent 
       confidence intervals were calculated for continuous 
       outcomes. We did not conduct any meta-analyses due to 
       heterogeneity. RESULTS: We identified four validated HRQL 
       measures: 36-Item Short Form Health Survey (SF-36), 
       National Eye Institute Visual Functioning Questionnaire 
       (VFQ-25 and -51), Visual Function Index (VF-14), and 
       Diabetes Treatment Satisfaction Questionnaire (DTSQ). We 
       also identified two tools that are currently undergoing 
       evaluation: the Retinopathy Treatment Satisfaction 
       Questionnaire (RetTSQ) and the Retinopathy Dependent 
       Quality of Life (RetDQoL). Two randomized controlled 
       trials (RCTs) reported on HRQL outcomes following anti-
       vascular endothelial growth factor (anti-VEGF) treatment 
       for DME. Seven observational studies reported on HRQL 
       outcomes following: laser photocoagulation (two), 
       vitrectomy (two), panretinal photocoagulation versus 
       vitrectomy (one), and phacoemulsification cataract surgery
       (two). The RCT comparing pegaptanib sodium versus sham 
       reported a statistically significant improvement from 
       baseline for the composite score of the VFQ-25 at 2 years 
       (but not at 1 year). The three-arm RCT comparing 
       ranibizumab monotherapy versus ranibizumab plus laser 
       versus laser showed a statisitically significant 
       difference for the composite score of the VFQ-25 for both 
       anti-VEGF arms versus laser at 1 year. The strength of 
       evidence for anti-VEGF was assessed as low. For the 
       remaining interventions, the studies were at high risk of 
       bias due to weak study designs (before-after and cohort 
       studies) and poor implementation. There is insufficient 
       evidence to determine whether one of these treatments for 
       DR is more effective than another in improving HRQL in 
       this patient population. CONCLUSIONS: We identified few 
       HRQL measurement instruments that have been used to assess
       the impact of treatment in patients with DR or DME; 
       however, the tools that have been used have been 
       adequately evaluated. Two tools developed specifically for
       patients with DR are currently undergoing evaluation. In 
       general, HRQL was improved following interventions for DR.
       Further research on HRQL following anti-VEGF treatment for
       DME is needed to confirm the results of two RCTs. The 
       current research on the impact of other interventions for 
       DR on HRQL is insufficient to draw conclusions about the 
       relative effect of one intervention versus another. RCTs 
       that assess the impact of treatments for DR should include
       HRQL as an outcome. 
655  2 Review. 
700 1  Johnson, Jeffrey A.|q(Jeffrey Allen),|d1965-|eauthor. 
700 1  Tennant, Matthew|q(Matthew T. S.),|eauthor. 
700 1  Rudnisky, Christopher,|eauthor. 
700 1  Dryden, Donna M.,|eauthor. 
710 2  University of Alberta Evidence-based Practice Center,
       |eissuing body. 
710 1  United States.|bAgency for Healthcare Research and Quality,
       |epublisher. 
710 2  National Library of Medicine|eissuing body. 
830  0 Technology assessment (Agency for Healthcare Research and 
       Quality) 
830  0 NCBI BookShelf 
856 40 |uhttp://www.ncbi.nlm.nih.gov/books/NBK248340|zConnect to 
       ebook (University of Melbourne only) 
990    National Center for Biotechnology Information 
990    Batch Ebook load (bud2) - do not edit, delete or attach 
       any records. 
991    |zNEW New collection NLM.bookshelf 2018-08-03 
Location Call No. Status
 UniM INTERNET resource    AVAILABLE